Skip to main content

Vertex-Pharmaceuticals-logo

Vertex says it has updated an R&D collaboration with Cystic Fibrosis Foundation Therapeutics (CFFT) stretching back more than a decade.

Under the updated Research, Development and Commercialization Agreement, disclosed in a regulatory filing yesterday, CFFT—the Foundation’s nonprofit drug discovery and development affiliate—agreed to pay Vertex $75 million upfront, as well as up to $6 million annually toward development funding.

{iframe}http://www.genengnews.com/gen-news-highlights/vertex-cf-foundation-therapeutics-expand-rd-collaboration/81253320{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.